Cost-Per-Responder Analysis of Tralokinumab Versus Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis in the US and Canada. J of Skin 2024, 8 (1), s317. https://doi.org/10.25251/skin.8.supp.317.